Skip to main content
Premium Trial:

Request an Annual Quote

Kenneth Buechler, Dirk van den Boom

Sequenom's board of directors has elected Kenneth Buechler its chairman, effective April 1. He succeeds Harry Hixson, who is retiring from the position after 11 years. Also, Dirk van den Boom was elected as a director, effective April 1.

Buechler has been on Sequenom's board since late 2009 and was previously president and CSO of Biosite, which he co-founded. Before that he was a senior research scientist for the diagnostics R&D group at Hybritech. 

Van den Boom is currently executive vice president and chief scientific and strategy officer at Sequenom. He will serve on the board's science committee.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.